Bio-Rad Laboratories, Inc.
BIO · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.18 | 0.02 | 0.46 |
| FCF Yield | 2.87% | 2.31% | 0.64% | 2.38% |
| EV / EBITDA | -4.74 | -15.93 | -3.00 | 3.99 |
| Quality | ||||
| ROIC | 2.37% | 2.14% | 2.87% | 2.28% |
| Gross Margin | 53.73% | 53.42% | 55.93% | 56.05% |
| Cash Conversion Ratio | -0.25 | -0.59 | -0.05 | 0.16 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.89% | -2.95% | 3.25% | 8.13% |
| Free Cash Flow Growth | 21.96% | 171.84% | -85.01% | 12.45% |
| Safety | ||||
| Net Debt / EBITDA | -0.41 | -1.53 | -0.21 | -0.04 |
| Interest Coverage | 5.50 | 6.83 | 12.66 | 322.59 |
| Efficiency | ||||
| Inventory Turnover | 1.56 | 1.59 | 1.72 | 2.24 |
| Cash Conversion Cycle | 260.35 | 253.35 | 237.12 | 175.17 |